← Back to Clinical Trials
Recruiting NCT06479421

NCT06479421 A Clinical Study for Developing Artificial Intelligence(AI)-Based Clustering Model for Personalized Medicine in Acute Respiratory Failure

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06479421
Status Recruiting
Phase
Sponsor Samsung Medical Center
Condition Acute Respiratory Failure
Study Type OBSERVATIONAL
Enrollment 250 participants
Start Date 2023-08-14
Primary Completion 2028-04-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 250 participants in total. It began in 2023-08-14 with a primary completion date of 2028-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The investigators will prospectively collect clinical information to develop a clustering analysis model and confirm phenotype for patients with acute respiratory failure who admit to the intensive care unit and require oxygen supply beyond a high flow nasal cannula, and a control group without acute respiratory failure. and clinical characteristics and prognosis will be compared.

Eligibility Criteria

\# Inclusion Criteria: \- Acute Respiratory Failure group Among patients admitted to the internal medicine intensive care unit at Samsung Seoul Hospital, if all of the following conditions are met: 1\) Age 18 or older 2) Patients who require treatment with high flow nasal cannula (HFNC), non-invasive ventilation (NIV (BIPAP or CPAP)), or mechanical ventilation (MV) due to acute respiratory failure. \- control group For comparative analysis, among patients admitted to the internal medicine intensive care unit at Samsung Seoul Hospital who meet all of the following conditions, they are registered as a control group with the consent of the subjects and undergo the same research procedure. 1. Age 18 or older 2. Patients who do not require high flow nasal cannula (HFNC), non-invasive ventilation (NIV (BIPAP or CPAP)), or mechanical ventilation (MV) treatment * Exclusion Criteria: If any of the following criteria applies, participants will not be permitted to participate in this clinical trial. 1. Patients 48 hours after oxygen treatment (HFNC, NIV (BIPAP or CPAP), MV) 2. Patients transferred from another hospital 3. Patients with limitations in treatment

Contact & Investigator

Central Contact

Ryoung Eun Ko, MD, PhD

✉ koryoungeun@gmail.com

📞 +82-2-3410-6399

Frequently Asked Questions

Who can join the NCT06479421 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Respiratory Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06479421 currently recruiting?

Yes, NCT06479421 is actively recruiting participants. Contact the research team at koryoungeun@gmail.com for enrollment information.

Where is the NCT06479421 trial being conducted?

This trial is being conducted at Seoul, South Korea.

Who is sponsoring the NCT06479421 clinical trial?

NCT06479421 is sponsored by Samsung Medical Center. The trial plans to enroll 250 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology